Why the Anteris Technologies (ASX:AVR) share price soared 23% today

The Anteris Technologies Ltd (ASX: AVR) share price rose an incredible 23% today after an online investor presentation yesterday.

| More on:
investor looking excited at rising fortescue share price on laptop

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Anteris Technologies Ltd (ASX: AVR) share price rose a jaw-dropping 23% today after an online investor presentation yesterday.

The healthcare company opened the day at $5.85 and idled until an incredible rally just after midday shot the share price to $6.86. At the time of writing, Anteris shares have dipped slightly to $6.79.

What does Anteris do?

Anteris, formerly known as Admedus Ltd, is a medical company that focuses on designing and manufacturing heart valves. Its next-generation technology re-engineers xenograft tissue into pure collagen scaffold, helping surgeons replace valves for patients during surgery.

What did Anteris showcase in its investor presentation?

Wayne Paterson, CEO and Managing Director of Anteris, presented 3 technologies to investors that the company is working on.

The first and oldest is an anti-calcification treatment platform called ADAPT. In his presentation, Mr Paterson claimed up to 20,000 people around the world have ADAPT technology inside their bodies at present.

DurAVR was the second technology showcased. DurAVR stands for Durable Aortic Valve Replacement. Unlike other valve systems, which are made from three tissue pieces sewn together, DurAVR is a single 3D valve model inserted into the patient.

The third technology is a catheter that is balloon expandable.

Mr Paterson also announced that the company should soon have a Food and Drug Administration (FDA) study approved regarding its DurAVR technology. He also claimed competitor valves could not go more than 150 million cycles while DurAVR had been recorded lasting as long as 700 million cycles. One cycle is the equivalent to one human heartbeat. 200 million cycles (the equivalent of 5 years inside the body) are required for a valve replacement to obtain FDA approval.

Anteris share price history

The Anteris share price has a volatile history, regularly going through periods of peaks and troughs.

In 2004 the share price was over $200 and as recently as 2016 was at or near $100. Anteris shares have been in long-term decline since. However, the share price has rallied over the past week and has been on a small upward trajectory from the beginning of 2021.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »